BCL2 and neoplasm: These results followed the trends identified in the cell experiments, displaying a decrease in tumor proliferation due to a reduced migration capacity [220], angiogenesis capacity [221], inflammation [220,221] (downregulation of NF-κB), increased apoptosis (mainly through the upregulation of the MAPK pathway and an increase in the Bax/Bcl2 ratio) [220,221,222,223], and anti-tumor immunity (including an increase in leukocytes) [222].